Perspectives
How does this impact clinical practice?
- New drugs aim to increase the anti-tumour immune response.
- There is a need to be highly selective about which patients receive some of these emerging options once they become available.
- For example, about half of patients drop out between the TIL harvest and infusion required for lifileucel therapy.